Frontline Targeted Therapy for METex14 Skip Mutation in NSCLC: Latest Updates from 2021
- Review METex14 skip mutation-driven lung cancer as an important subgroup with
- Discuss emerging targeted therapies in patients with METex14 skip mutations.
- Discuss latest 2021 clinical data for targeted therapies against METex14 skip
mutations (ASCO/WCLC/ESMO 2021).
Dr. Barbara Melosky
Dr. Johan Vansteenkiste
This program has been made possible through unrestricted support from Novartis.